Last reviewed · How we verify
BT8009
At a glance
| Generic name | BT8009 |
|---|---|
| Sponsor | BicycleTx Limited |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer (PHASE2)
- Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer (PHASE2)
- Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BT8009 CI brief — competitive landscape report
- BT8009 updates RSS · CI watch RSS
- BicycleTx Limited portfolio CI